Suppr超能文献

术前甲状腺球蛋白测量在甲状腺癌复发风险和治疗反应中的应用。

Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy.

机构信息

Division of GI, Trauma, and Endocrine Surgery, Department of Surgery, University of Colorado School of Medicine, 12631 E 17th Ave., C-313 Mail Stop, Aurora, CO, 80045, United States.

Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, 12801 E. 17th Ave., 7103, Research 1 South, Aurora, CO, 80045, United States; Department of Biomedical Informatics, University of Colorado School of Medicine, 1890 N. Revere Court, Mailstop F600, Aurora, CO, 80045, United States.

出版信息

Am J Surg. 2024 Dec;238:115818. doi: 10.1016/j.amjsurg.2024.115818. Epub 2024 Jul 3.

Abstract

BACKGROUND

Thyroid cancer has an overall favorable prognosis, but no pre-operative biochemical marker has been shown to distinguish between low and high-risk disease or predict response to therapy.

METHODS

We retrospectively reviewed 162 patients that underwent thyroid surgery for thyroid cancer between 2006 and 2022 in whom a pre-operative thyroglobulin level (Tg) was measured. We subdivided patients into low, intermediate and high-risk thyroid cancer and based on their response to therapy per ATA guidelines.

RESULTS

We showed that as pre-operative Tg level increased, patients were more likely to have high-risk disease (p ​< ​0.01). We found a linear association between the primary tumor size and high-risk histology with pre-operative Tg (p ​< ​0.01). Pre-operative Tg level was significantly associated with response to therapy following initial surgical management. Specifically, as pre-operative Tg increases, patients were less likely to achieve an excellent response (p ​< ​0.01).

CONCLUSIONS

Our retrospective analysis demonstrated that pre-operative Tg is significantly associated with ATA structural risk of recurrence and response to therapy and may have the potential to guide initial therapy and follow-up management.

摘要

背景

甲状腺癌总体预后良好,但尚无术前生化标志物可区分低危和高危疾病,或预测对治疗的反应。

方法

我们回顾性分析了 2006 年至 2022 年间因甲状腺癌接受甲状腺手术的 162 例患者,这些患者在术前测量了甲状腺球蛋白(Tg)水平。我们将患者分为低危、中危和高危甲状腺癌,并根据 ATA 指南中对治疗的反应进行了分类。

结果

我们发现,随着术前 Tg 水平的升高,患者更有可能患有高危疾病(p < 0.01)。我们发现术前 Tg 与原发肿瘤大小和高危组织学之间存在线性关联(p < 0.01)。术前 Tg 水平与初始手术治疗后的治疗反应显著相关。具体而言,随着术前 Tg 的升高,患者不太可能获得优异的反应(p < 0.01)。

结论

我们的回顾性分析表明,术前 Tg 与 ATA 复发结构风险和对治疗的反应显著相关,可能有潜力指导初始治疗和随访管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验